VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 335 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2017. The put-call ratio across all filers is 1.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $16,000 | +77.8% | 1,096 | +188.4% | 0.01% | +100.0% |
| Q3 2016 | $9,000 | -75.7% | 380 | +5.3% | 0.00% | -62.5% |
| Q4 2015 | $37,000 | -99.5% | 361 | -99.1% | 0.01% | -99.6% |
| Q3 2015 | $6,800,000 | -18.5% | 38,008 | +1.0% | 2.24% | -7.3% |
| Q2 2015 | $8,342,000 | +0.3% | 37,619 | -10.8% | 2.41% | -3.0% |
| Q1 2015 | $8,314,000 | +14.6% | 42,155 | -16.8% | 2.48% | +37.5% |
| Q4 2014 | $7,253,000 | -7.5% | 50,667 | -15.3% | 1.81% | +7.0% |
| Q3 2014 | $7,840,000 | +211.7% | 59,824 | +200.8% | 1.69% | +206.9% |
| Q2 2014 | $2,515,000 | +93.0% | 19,891 | +100.9% | 0.55% | +91.0% |
| Q1 2014 | $1,303,000 | -86.9% | 9,900 | -88.3% | 0.29% | -86.3% |
| Q4 2013 | $9,967,000 | +30.2% | 84,964 | +15.6% | 2.10% | +31.5% |
| Q3 2013 | $7,656,000 | +15.9% | 73,491 | -4.1% | 1.60% | +13.7% |
| Q2 2013 | $6,607,000 | – | 76,645 | – | 1.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |